Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00030667
Other study ID # NCI-2012-01869
Secondary ID NCI-2012-01869CD
Status Completed
Phase Phase 2
First received February 14, 2002
Last updated April 14, 2015
Start date May 2002
Est. completion date December 2005

Study information

Verified date December 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have relapsed or refractory solid tumors of childhood. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth.


Description:

OBJECTIVES:

I. Determine the response rate of patients with relapsed or refractory pediatric solid tumors treated with imatinib mesylate.

II. Determine the toxicity of this drug in these patients. III. Determine the time to progression in patients treated with this drug. IV. Determine the pharmacokinetics of this drug in these patients. V. Correlate response with c-kit and platelet-derived growth factor receptor expression in patients treated with this drug.

OUTLINE: This is a multicenter study. Patients are stratified according to disease (Ewing's sarcoma/primitive neuroectodermal tumor vs osteosarcoma vs neuroblastoma vs other).

Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date December 2005
Est. primary completion date December 2005
Accepts healthy volunteers No
Gender Both
Age group N/A to 30 Years
Eligibility Inclusion Criteria:

- Histologically confirmed solid tumors including the following:

- Ewing's sarcoma

- Bone or soft tissue primitive neuroectodermal tumor

- Osteosarcoma

- Neuroblastoma

- Desmoplastic small round cell tumor

- Synovial cell sarcoma

- Gastrointestinal stromal tumor (GIST)

- Metastatic pulmonary disease eligible

- No pleural effusion of any size or definite radiologic evidence of pleural-based disease

- Recurrent or refractory to conventional therapy

- GIST eligible at initial presentation

- Tumor tissue blocks must be available

- At least 1 measurable lesion

- At least 20 mm by conventional techniques

- At least 10 mm by spiral CT scan

- Lesions assessable only by radionuclide scan are not considered measurable

- Performance status - Lansky 50-100% (= 10 years of age)

- Performance status - Karnofsky 50-100% (> 10 years of age)

- At least 2 months

- Absolute neutrophil count = 1,000/mm^3*

- Platelet count = 75,000/mm^3* (transfusion independent)

- Hemoglobin = 8.0 g/dL* (RBC transfusions allowed)

- Bilirubin = 1.5 times upper limit of normal (ULN)

- ALT = 2.5 times ULN

- INR < 1.5

- PTT = ULN

- Fibrinogen = lower limit of normal

- Creatinine normal for age

- Glomerular filtration rate = 70 mL/min

- No uncontrolled infection

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective barrier contraception

- At least 1 week since prior biologic therapy or immunotherapy and recovered

- At least 1 week since prior growth factors

- No concurrent immunomodulating agents

- At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered

- No concurrent chemotherapy

- No concurrent steroids

- Recovered from prior radiotherapy

- At least 2 weeks since prior local palliative radiotherapy (small port)

- At least 3 months since prior craniospinal radiotherapy or radiotherapy to 50% or more of pelvis

- At least 6 weeks since other prior substantial bone marrow radiation

- No concurrent radiotherapy during first course of treatment

- Concurrent palliative radiotherapy to local painful lesions allowed after first course of treatment provided there is no evidence of disease progression and at least 1 measurable lesion remains outside radiation port

- No concurrent therapeutic doses of warfarin

- No concurrent anticonvulsants that induce the cytochrome p450 enzyme system (e.g., phenytoin, carbamazepine, and phenobarbital)

- Concurrent benzodiazepines and gabapentin allowed

- Concurrent low-molecular weight heparin allowed

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
imatinib mesylate
Given orally
Other:
laboratory biomarker analysis
Correlative studies
pharmacological study
Correlative studies

Locations

Country Name City State
United States Children's Oncology Group Arcadia California

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response rate, determined using the RECIST criteria 95% confidence interval will be computed. Up to 2 years No
Primary Toxicity reported using the CTC version 2.0 Up to 2 years Yes
Secondary Time to disease progression Calculated by the method of Kaplan and Meier. Up to 2 years No
See also
  Status Clinical Trial Phase
Recruiting NCT04933669 - Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors Phase 2
Completed NCT01769248 - Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle N/A
Completed NCT01774162 - EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration N/A
Completed NCT01110668 - Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) Phase 2
Terminated NCT00091078 - Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery Phase 2
Completed NCT00025246 - Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery Phase 2
Active, not recruiting NCT00265798 - Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate Phase 2
Recruiting NCT04143048 - A Study on Non-invasive Early Diagnosis of Gastrointestinal Stromal Tumors and Differentiation of Benign and Malignant Nodules
Recruiting NCT02931981 - Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor N/A
Not yet recruiting NCT02576080 - Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index Phase 3
Recruiting NCT01389583 - A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients Phase 2
Recruiting NCT00777504 - Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Phase 4
Completed NCT00769782 - Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor Phase 2
Completed NCT00764595 - Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor Phase 2
Completed NCT00098579 - Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery Phase 1
Completed NCT00005862 - SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas Phase 2
Completed NCT00004895 - Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery Phase 2
Recruiting NCT02776878 - A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST N/A
Completed NCT01751919 - A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I) Phase 1
Completed NCT01267695 - Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor Phase 2